Cancer Diagnostics Market: By Product Type (Next-generation Sequencing, Microarrays, PCR, Flow Cytometry, In situ Hybridization, Immunohistochemistry, Imaging Instruments, & Biopsy), By Cancer Treated & By Geography-Forecast (2016-2021)
[Lowest Price Guaranteed: $5,250]
Related Topics: Abbott , Blood , Breast Cancer , Cancer , Colorectal Cancer , Healthcare , Ovarian Cancer , Pancreatic Cancer , Prostate Cancer
Cancer can be defined as abnormal division of cells in an uncontrollable fashion. This uncontrollable division of cells starts with a single cell which grow and multiply to form tumor in the body. Globally increasing instances of deaths due to cancer and people with cancer coupled with increasing awareness and developing healthcare infrastructure is expected to drive the demand for cancer diagnostics market during the period of study.
This report identifies the cancer diagnostics market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to cancer diagnostics market.
Globally North America dominated the market for cancer diagnostics in 2015 due to higher usage of the latest and advanced technologies for treatment, high awareness and reported instances of cancer in the region coupled with easy accessible and highly developed health care infrastructure. North America is expected to continue its domination during the period of study and was followed by Europe and Asia-Pacific as the second and third largest markets respectively in 2015. However Asia-Pacific is expected to be the fastest growing market due to technological advancement in the field of medical science, increasing medical tourism, and rapidly developing health care infrastructure in the region coupled with increasing awareness about cancer in the region.
This report on global cancer diagnostics also covers different type of cancer diagnostics product available, various cancer treated and market size in various geographical regions.
On the basis of type of cancer diagnostics product available, this report classified as follows covering all major types of cancer diagnostics product available in the market: Next-generation Sequencing, Microarrays, PCR, Flow Cytometry, In situ Hybridization, Immunohistochemistry, Imaging Instruments (MRI, CT, PET, Ultrasound, Mammography), Biopsy
On the basis of cancer treated with cancer diagnostics this report covers all the major cancer treated using cancer diagnostics: Breast Cancer, Prostate Cancer, Ovarian Cancer, Thyroid Cancer, Kidney Cancer, Blood Cancer, Colorectal Cancer, Liver Cancer, Pancreatic Cancer and Others
This is report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for cancer diagnostics in each of the region.
This report identifies all the major companies operating in the global cancer diagnostics market. Some of the major companies’ profiles in detail are as follows:
Thermo Fisher Scientific, Inc.
GE Healthcare (A Subsidiary of General Electric Company)
Abbott Laboratories, Inc.
Becton, Dickinson and Company
Table of Contents
for Cancer Diagnostics Market: By Product Type (Next-generation Sequencing, Microarrays, PCR, Flow Cytometry, In situ Hybridization, Immunohistochemistry, Imaging Instruments, & Biopsy), By Cancer Treated & By Geography-Forecast (2016-2021)
1. Cancer Diagnostics – Market Overview
2. Executive Summary
3. Cancer Diagnostics Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End User Profiling
3.2.3. Top 5 Financials Analysis
4. Cancer Diagnostics – Market Forces
4.1.1. Increasing global instances of cancer and cancer related deaths
4.1.2. Easy accessibility to healthcare institutions
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition
5. Cancer Diagnostics Market– Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors
6. Global Cancer Diagnostics Market, By Product Type (2014-2021)
6.1. Next-generation Sequencing
6.4. Flow Cytometry
6.5. In situ Hybridization
6.7. Imaging Instruments (MRI, CT, PET, Ultrasound, Mammography)
7. Global Cancer Diagnostics Market, By Cancer Treated (2014-2021)
7.1. Breast Cancer
7.2. Prostate Cancer
7.3. Ovarian Cancer
7.4. Thyroid Cancer
7.5. Kidney Cancer
7.6. Blood Cancer
7.7. Colorectal Cancer
7.8. Liver Cancer
7.9. Pancreatic Cancer
8. Global Cancer Diagnostics Market, By Geography (2014-2021)
8.1.7. Rest of Europe
8.2. Asia Pacific
8.2.4. South Korea
8.2.5. Rest of Asia-Pacific
8.3. North America
8.4. Rest of the World (RoW)
8.4.2. Rest of RoW
9. Cancer Diagnostics – Market Entropy
9.2. Technological Developments
9.3. Merger & Acquisitions, and Joint Ventures
9.4. Supply- Contract
10. Company Profiles (Top 10 Companies)
10.1. Thermo Fisher Scientific, Inc.
10.1.3. Key Insights
10.1.4. Key Strategy
10.1.5. Product Portfolio
10.1.6. SWOT Analysis
10.2. GE Healthcare (A Subsidiary of General Electric Company)
10.2.3. Key Insights
10.2.4. Key Strategy
10.2.5. Product Portfolio
10.2.6. SWOT Analysis
10.3. Abbott Laboratories, Inc.
10.3.3. Key Insights
10.3.4. Key Strategy
10.3.5. Product Portfolio
10.3.6. SWOT Analysis
10.4. Becton, Dickinson and Company
10.4.3. Key Insights
10.4.4. Key Strategy
10.4.5. Product Portfolio
10.4.6. SWOT Analysis
10.5. Siemens Healthcare
10.5.3. Key Insights
10.5.4. Key Strategy
10.5.5. Product Portfolio
10.5.6. SWOT Analysis
10.6. Agilent Technologies, Inc.
10.6.3. Key Insights
10.6.4. Key Strategy
10.6.5. Product Portfolio
10.6.6. SWOT Analysis
10.7.3. Key Insights
10.7.4. Key Strategy
10.7.5. Product Portfolio
10.7.6. SWOT Analysis
10.8. C.R. Bard, Inc.
10.8.3. Key Insights
10.8.4. Key Strategy
10.8.5. Product Portfolio
10.8.6. SWOT Analysis
10.9. Illumina, Inc.
10.9.3. Key Insights
10.9.4. Key Strategy
10.9.5. Product Portfolio
10.9.6. SWOT Analysis
10.10.3. Key Insights
10.10.4. Key Strategy
10.10.5. Product Portfolio
10.10.6. SWOT Analysis
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11.3. Research Methodology
11.4. Expert Insights
List Of Tables
in Cancer Diagnostics Market: By Product Type (Next-generation Sequencing, Microarrays, PCR, Flow Cytometry, In situ Hybridization, Immunohistochemistry, Imaging Instruments, & Biopsy), By Cancer Treated & By Geography-Forecast (2016-2021)
80148 | HCR 0195
|Title||Date Published||Price from||More Details|
|Physician Views: Is the HER2-positive breast cancer extended adjuvant opportunity big enough to support neratinib's blockbuster forecasts?|
Scope Top-line data from the ExteNET study – which were released earlier this week – appear to estab...
|28 Jul 2014 by FirstWord Pharma||USD $695||More Info|
|Physician Views: Avastin to lose share as front-line therapy for first-line metastatic colorectal cancer?|
Scope Two recent developments appear poised to shift the typical US-based treatment regimen for firs...
|13 Jul 2014 by FirstWord Pharma||USD $695||More Info|
|The Future of Cancer Immunotherapy: KOL Views Bring Opportunities into Sharp Focus|
IntroductionThere has been considerable media hype and clinical interest in cancer immunotherapy in ...
|01 Jul 2014 by FirstWord Pharma||USD $4,995||More Info|
|Physician Views: Expanded access in cancer – how are oncologists utilising this opportunity?|
Scope According to analysts at Barclays, oncology continues to attract around one-third of pharma's ...
|28 Apr 2014 by FirstWord Pharma||USD $695||More Info|
|Breast Cancer: New targeted therapies transform treatment - KOL Insight|
IntroductionThe introduction of targeted therapies revolutionised the breast cancer market, widening...
|10 Feb 2014 by FirstWord Pharma||USD $7,900||More Info|
|Physician Views: Bayer's M&A catalyst – is Xofigo a paradigm shifter for the prostate cancer market?|
Scope Already positioned as one of the most commercially promising new drug approvals of 2013, Alget...
|01 Dec 2013 by FirstWord Pharma||USD $695||More Info|
|KOL Insight: Prostate Cancer: Competition intensifies in race to the top|
IntroductionThe Prostate Cancer market has seen a number of progressive changes in recent years. The...
|01 Nov 2013 by FirstWord Pharma||USD $7,900||More Info|
|Consensus Outlook: Prostate Cancer- Competition intensifies in race to the top|
IntroductionCharting the Future Prostate Cancer Market LandscapeThe prostate cancer market has exper...
|01 Nov 2013 by FirstWord Pharma||USD $4,995||More Info|
|Colorectal Cancer -- KOL Insight Module|
IntroductionThe global market for colorectal cancer (CRC) drugs is undergoing a fundamental shift du...
|01 Oct 2013 by FirstWord Pharma||USD $7,900||More Info|
|Physician Views: What is reaction among urologists, oncologists to the Xtandi PREVAIL data – can it displace Zytiga in the pre-chemotherapy prostate cancer setting?|
ScopeThe prostate cancer market looks poised to enter its next stage of evolution in 2014, with Medi...
|01 Oct 2013 by FirstWord Pharma||USD $695||More Info|